-
Statement
Letter to President Biden, Secretary Becerra, Speaker Pelosi, Minority Leader McCarthy, Senate Majority Leader Schumer, and Senate Minority Leader McConnell opposing HR 3
09.08.2021
Members of the VC community voice concerns over HR 3 to policymakers
-
Video
An NPLB Animation: Fighting for Affordable Medicines & Encouraging Innovation
08.17.2021
Credit: No Patient Left Behind
-
Article
Investors Want New Drugs for a Better World — and a Return on Their Money
07.07.2021
One truth stays constant: In the long run, H.R. 3 would hurt the very patients Democrats want to help. Here’s why.
-
Statement
Incubate Statement on Introduction of the PASTEUR Act
06.22.2021
Incubate commends Senators Michael Bennet (D-CO) and Todd Young (R-IN) and Representatives Mike Doyle (D-PA) and Drew Ferguson (R-GA) for re-introducing the Pioneering Antimicrobial Subscriptions to End Up surging Resistance (PASTEUR) Act.
-
Article
What M&A Critics Don’t Understand About Drug Innovation
06.14.2021
We want brilliant minds at thousands of small, unheard-of biotechs chasing tomorrow’s cures. But they can only do so if larger manufacturers help ensure their ideas are safe, effective, and actually reach patients.
-
Article
As Washington Ties Pharma’s Hands, China Is Leaping Ahead
06.11.2021
American policy should be focused on protecting, rather than undermining, the global dominance of our biotechnology industry.
-
Video
-
Video
The Investor’s Paradox
06.11.2021
-
Statement
Incubate Raises Concern About President Biden’s Support of WTO TRIPS Waiver
05.06.2021
In response to the Biden Administration’s recent announcement that the U.S. will support waiving intellectual property protections for COVID-19 vaccines, the Executive Director of Incubate, John Stanford, issued the following statement
-
Statement
Life Science Investors & Early Stage Ecosystem Raise Concern with Reintroduction of H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act
04.22.2021
Incubate strongly opposes HR 3, which was reintroduced today. The decision to pursue price controls is unfortunate. Moreover, the decision to propose this while the life sciences industry continues to drive health and economic recovery amid a pandemic is unfathomable.
-
Article
CBO Report: Research and Development in the Pharmaceutical Industry
04.08.2021
CBO assesses trends in spending for prescription drug research and development (R&D) and the introduction of new prescription drugs. CBO...
-
Article
Throwing Away Drug Patents Won’t Cure Anything
04.05.2021
With the pandemic still raging, does it make sense to enforce patents on COVID-19 vaccines and therapeutics?